FDA
-
-
-
-
-
-
-
J&J myeloma drug combo cuts disease progression risk by 89% in trial
-
-
-
-
-
-
-
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
-
-
-
-
-
-
-
Johnson & Johnson reports positive results for rare blood disorder treatment
-
-
-
-
-
-
-
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
-
-
-
-
-
-
-
FDA approves expanded TREMFYA label for joint damage prevention
-
-
-
-
-
-
-
Johnson & Johnson reports positive phase 2b results for experimental IBD therapy
-
-
-
-
-
-
-
FDA grants priority review to J&J's IMAAVY for rare blood disorder
-
327,488 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

